К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 9 min

Kidney cancer: targeted therapy and immunotherapy, and how treatment is chosen

How kidney cancer is treated: surgery in early stages, adjuvant therapy, IMDC risk groups, combinations of immunotherapy and targeted drugs, second line and side effects.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026

Kidney cancer (renal cell carcinoma) is treated differently depending on the stage. If the tumour is only in the kidney, the main method is surgery. If there are metastases, the basis of treatment is targeted drugs and immunotherapy rather than conventional chemotherapy, because this type of tumour is resistant to it.

In this article I explain which types of kidney cancer exist, what decides the choice after surgery, how the IMDC risk groups work, which combinations are used for metastases, which side effects to expect and what to do at progression.

Types of kidney cancer

Most cases are clear cell renal cell carcinoma. Other types are less common and are treated in their own way.

Type Features
Clear cell The most common; well studied, with main regimens built on immunotherapy and targeted drugs
Papillary Subtypes are distinguished; regimens are chosen separately, sometimes with different drugs
Chromophobe Usually slower; less data on systemic treatment
Rare types (medullary, collecting duct, translocation) Need discussion at a specialised centre

The doctor also takes into account sarcomatoid features in the tumour: they point to aggressive behaviour, but such tumours often respond well to immunotherapy. If the report contains unclear wording, it is useful to review the slides or discuss the report at a tumour board.

How the diagnosis and stage are determined

A kidney mass is usually found by chance on ultrasound or CT. To clarify it, CT or MRI with contrast and chest CT are done, and when metastases are suspected, other tests (brain MRI, bone scan or PET-CT). Biopsy is not always needed: if the mass will clearly be removed, the diagnosis is confirmed by histology after surgery. Biopsy is done when treatment will not start with surgery (for example with metastases or before ablation) or when the nature of the mass is unclear.

The stage is determined by the TNM system: tumour size, involvement of the vein, adrenal gland, surrounding fat, lymph nodes and distant organs.

Treatment of early stages

In a localised tumour the main goal is to remove it completely.

  • Partial nephrectomy (kidney-sparing surgery) is possible for small and conveniently located tumours. It preserves kidney function and is usually preferable when technically feasible.
  • Radical nephrectomy (removal of the kidney) is needed for large tumours or when partial removal is impossible.
  • Ablation (radiofrequency, cryoablation) is considered for small tumours and high surgical risk.
  • Surveillance (active surveillance with regular imaging) is discussed for very small masses in older or frail patients.

Chemotherapy is not given after surgery, because it does not lower the risk of relapse in this type of cancer.

Adjuvant therapy after surgery

If the risk of recurrence is high, adjuvant immunotherapy is discussed. According to the KEYNOTE-564 trial, pembrolizumab for about a year after surgery in patients with clear cell cancer and a high risk of recurrence lowered the chance of recurrence and improved survival. The decision depends on stage, Fuhrman or ISUP grade, involved lymph nodes or removed metastases, and on your condition and coexisting illnesses (in particular autoimmune ones). More on how such treatment works and its side effects: immunotherapy and immunotherapy side effects. General approach to treatment after surgery: neoadjuvant and adjuvant therapy.

Treatment of metastatic disease: IMDC risk groups

When the cancer has spread (most often to the lungs, bones, lymph nodes, liver, adrenal glands or brain), the basis of treatment is systemic therapy. To choose the regimen, the IMDC risk group is assessed. Six factors are counted:

  1. less than a year has passed from diagnosis to the start of systemic treatment;
  2. general condition below 80% on the Karnofsky scale;
  3. haemoglobin below normal;
  4. blood calcium above normal;
  5. neutrophils above normal;
  6. platelets above normal.
Number of factors Risk group
0 Favourable
1–2 Intermediate
3 or more Poor

First line in metastatic disease

Modern guidelines rely on two main approaches:

  • immunotherapy plus a targeted drug (tyrosine kinase inhibitor): for example pembrolizumab with axitinib or lenvatinib, nivolumab with cabozantinib;
  • dual immunotherapy: nivolumab with ipilimumab (more often in intermediate and poor risk).

In some patients with favourable risk and a small volume of disease, a single targeted drug (for example sunitinib, pazopanib, cabozantinib) is also possible, especially when immunotherapy is unsuitable. The doctor chooses, taking into account the risk group, the volume of metastases, coexisting illnesses (for example autoimmune ones), cardiovascular risk and drug availability. How such drugs work is explained in the articles targeted therapy and immunotherapy.

To assess response, CT or MRI is done every 2–3 months at the start of treatment and less often later. How to read the report is covered in the glossary entry RECIST.

The role of surgery in metastatic disease

Once, nephrectomy was done in almost all patients with metastases. Today it is decided individually: cytoreductive nephrectomy remains an option for selected patients with good condition, a limited volume of metastases and favourable risk, but not for everyone. Sometimes systemic therapy is given first and nephrectomy is considered after a response. Removal or irradiation of single metastases (oligometastases) may be justified: see the entry oligometastases.

Side effects and how to live with them

Targeted drugs (tyrosine kinase inhibitors):

  • raised blood pressure (often and early, so blood pressure is measured at home and agreed in advance with a primary care doctor or cardiologist);
  • hand-foot syndrome (more: hand-foot syndrome);
  • diarrhoea, nausea, loss of taste, mouth sores;
  • weakness and reduced thyroid function;
  • protein in urine, raised liver enzymes;
  • impaired wound healing and risk of bleeding (so before surgery and procedures the regimen is sometimes paused).

Immunotherapy:

  • inflammation of the bowel, lungs, liver, skin and endocrine glands (thyroid, adrenals, pituitary);
  • weakness, rash, itching, shortness of breath, diarrhoea.

Many complications are easily managed with early contact. If you are not sure how serious a symptom is, use the symptom checker for treatment.

What to do if treatment stops working

Progression does not mean there are no options, but it changes the plan. Before changing therapy it must be confirmed on repeat scans (pseudoprogression occurs on immunotherapy), tolerance should be assessed and the need for biopsy considered. In second line the following are used:

  • another targeted drug (cabozantinib, axitinib, lenvatinib with everolimus);
  • in some countries belzutifan (an HIF-2α inhibitor);
  • clinical trials.

More on the logic of changing treatment: progression on treatment and clinical trials.

Metastases to bone, brain and lung

Metastases of kidney cancer often respond well to local treatment. For bone metastases radiotherapy and bone-protecting drugs are important, more in bone metastases. For single brain lesions stereotactic radiotherapy is used. Pain must be treated in parallel: pain relief in cancer.

Follow-up after treatment

After surgery patients have regular CT or MRI, more often in the first years, and blood tests. The exact schedule depends on stage and risk and is set by the treating doctor. Recurrence is possible even after several years, so do not skip check-ups: more in cancer recurrence after years.

What to ask your doctor

  • What type of kidney cancer do I have and what is the stage?
  • Which IMDC risk group am I in, if there are metastases?
  • Is adjuvant immunotherapy suitable for me after surgery?
  • Which first-line regimen is recommended and why not another?
  • How will we assess the effect and how often should CT be done?
  • Which side effects are most likely, how to recognise them and when to call?
  • What do we do if treatment stops working?
  • Should genetic testing be discussed?

When to seek urgent help

Call your doctor the same day or call an ambulance if:

  • temperature is 38 °C or above, or you have chills;
  • blood pressure is above 180/110 or you have a severe headache with vision problems;
  • severe diarrhoea (more than 6 times a day), vomiting, you cannot drink;
  • shortness of breath, chest pain, coughing up blood;
  • severe weakness of an arm or leg, seizures, speech problems;
  • blood in urine or stool, severe abdominal pain.

Can I get a second opinion

In metastatic kidney cancer the choice of first line affects later steps, so a second opinion is useful before starting or before a change of therapy. Especially if:

  • you were offered chemotherapy as the main treatment;
  • the risk group was not assessed or immunotherapy was not discussed;
  • after surgery adjuvant treatment was not discussed despite high risk;
  • it is unclear whether surgery is needed with metastases.

List of documents: documents for a second opinion and preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: urological tumours.

Sources

  1. Renal Cell Cancer Treatment (PDQ) — National Cancer Institute
  2. ESMO Clinical Practice Guidelines — ESMO
  3. Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
  4. Clinical guidelines (Russia) — Russian Ministry of Health

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.